Bringing patient centricity to diabetes medication access in Canada

References

• Canadian Institute for Health Information (CIHI)CIHI International Comparisons: A Focus on Diabetes2015 Available from: https://secure.cihi.ca/free_products/oecd-diabetes-report-2015_en.pdfAccessed May 19, 2016
   Google Scholar
• Canadian Diabetes Association (CDA)2015 Report on Diabetes – Driving Change Available from: https://www.diabetes.ca/publications-newsletters/advocacy-reports/2015-report-on-diabetes-driving-changeAccessed May 19, 2016
   Google Scholar
• Canadian Diabetes Association (CDA)Diabetes Charter for CanadaOttawaCDA2014 Available from: www.mydiabetescharter.caAccessed July 5, 2016
   Google Scholar
• Canadian Institute for Health Information (CIHI)Prescribed drug spending in Canada, 2013: a focus on public drug programs2015 Available from: https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC2896&lang=enAccessed July 5, 2016
   Google Scholar
• Innovative Medicines Canada2016 annual report: access to new medicines in public drug plans - Canada and Comparable Countries2016 Available from: http://innovativemedicines.ca/canadians-facing-delayed-access-to-new-innovative-medicines-reportAccessed July 1, 2016
   Google Scholar
• Ontario public drug programs – how drugs are approved Available from: http://www.health.gov.on.ca/en/pro/programs/drugs/how_drugs_approv/how_drugs_approv.aspxAccessed July 6, 2016
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH)Common Drug Review (CDR) Available from: https://www.cadth.ca/about-cadth/what-we-do/products-services/cdrAccessed July 5, 2016
   Google Scholar
• The pan-Canadian Pharmaceutical Alliance Available from: http://canadaspremiers.ca/en/initiatives/358-pan-canadian-pharmaceutical-allianceAccessed July 5, 2016
   Google Scholar
• CADTH Optimal Use Report: Third-Line Pharmacotherapy for Type 2 Diabetes – Update31B2013 Available from: https://www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdfAccessed July 6, 2016
   Google Scholar
• CADTH Common Drug Review (CDR) reports Available from: https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/reportsAccessed July 19, 2016
   Google Scholar
• CADTH Canadian Drug Expert Committee (CDEC)Final Recommendation: Dulaglutide2016 Available from: https://www.cadth.ca/sites/default/files/cdr/complete/SR0462_complete_Trulicity_June_21_16_e.pdfAccessed July 19, 2016
   Google Scholar
• Canadian Diabetes AssociationFormulary listings for diabetes medications in Canada2016 Available from: http://www.diabetes.ca/publications-newsletters/advocacy-reports/provincial-territorial-formulary-chartAccessed July 1, 2016
   Google Scholar
• Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada Available from: http://guidelines.diabetes.ca/?_ga=1.159114236.730924813.1463669350Accessed May 19, 2016
   Google Scholar
• LeiterLABerardLBoweringCKType 2 diabetes mellitus management in Canada: is it improving?Can J Diabetes2013372828924070797
   PubMed Web of Science ®Google Scholar
• KhuntiKWoldenMLThorstedBLAndersenMDaviesMJClinical inertia in people with type 2 diabetesDiabetes Care201336113411341723877982
   PubMed Web of Science ®Google Scholar
• Mata-CasesMBenito-BadorreyBRoura-OlmedaPClinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary careCurr Med Res Opin201329111495150223944631
   PubMed Web of Science ®Google Scholar
• RajpathakRajgopalanSEngelSSImpact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapyJ Diabetes Complications201428683183525104238
   PubMed Web of Science ®Google Scholar
• StrainWDBlüherMPaldániusPClinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes?Diabetes Ther20145234735425113408
   PubMed Web of Science ®Google Scholar
• ReachGClinical inertia, uncertainty and individualized guidelinesDiabetes Metab201440424124524559857
   PubMed Web of Science ®Google Scholar
• DesprésFForgetAKettaniF-ZBlaisLImpact of patient reimbursement timing and patient out-of-pocket expenses on medication adherence in patients covered by private drug insurance plansJ Manag Care Spec Pharm201622553954727123915
   PubMed Web of Science ®Google Scholar
• GomesTMartinsDTadrousMSelf-monitoring of blood glucose levels: evaluating the impact of a policy of quantity limits on test-strip use and costsCan J Diabetes Epub2016517
   Web of Science ®Google Scholar
• PeyrotMBurnsKKDaviesMDiabetes attitudes wishes and needs 2 (DAWN2): a multinational, multi-stakeholder study or psychosocial issues in diabetes and person-centred diabetes careDiabetes Res Clin Pract201399217418423273515
   PubMed Web of Science ®Google Scholar
• NicolucciAKovacs BurnsKHermannsNDiabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetesDiabet Med201330776777723711019
   PubMed Web of Science ®Google Scholar
• HoltRINicolucciAKovacs BurnsKDiabetes attitudes, wishes and needs second study (DAWN2™): cross-national comparisons on barriers and resources for optimal care – healthcare professional perspectiveDiabet Med201330778979823710839
   PubMed Web of Science ®Google Scholar
• Kovacs BurnsKNicolucciAHoltRIDiabetes attitudes, wishes and needs second study (DAWN2™): cross-national benchmarking indicators for family members living with people with diabetesDiabet Med201330777878823701236
   PubMed Web of Science ®Google Scholar
• PeyrotMon behalf of DAWN2 Study GroupMulti-stakeholder study and strong action platform to promote person-centred diabetes careDiabetes Voice201358Special Issue 21316 Available from: http://www.idf.org/diabetesvoice/issues/volume-58-special-issue-2Accessed May 23, 2016
   Google Scholar
• SkovlundSPeyrotMThe Diabetes Attitudes, Wishes, and Needs (DAWN) program: a new approach to improving outcomes of diabetes careDiabetes Spect2005183136142 Available from: http://dx.doi.org/10.2337/diaspect.18.3.136Available May 23, 2016
   Google Scholar
• Statistics CanadaSurvey on Living with Chronic Diseases in Canada (SLCDC) 2011 [Internet]Ottawa, ONStatistics Canada2011 Available from http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SurvId=84769&InstaId=84771&SDDS=5160Accessed October 25, 2015
   Google Scholar
• Canadian Diabetes Association (CDA)Report on diabetes: driving change2015 Available from: http://www.diabetes.ca/publications-newsletters/advocacy-reports/2015-report-on-diabetes-driving-changeAccessed July 1, 2016
   Google Scholar
• Kovacs BurnsKVallisMRossSHollahanDHahnJDiabetes Attitudes, Wishes and Needs Second Study (DAWN2™): psychosocial experiences of Canadian family members living with people with diabetesDiabetes Res Treat Open Access201522
   Google Scholar
• VallisMKovacs BurnsKHollahanDRossSHahnJDiabetes Attitudes, Wishes and Needs Second Study (DAWN2™): understanding diabetes-related psychosocial outcomes for Canadians with diabetesCan J Diabetes201640323424126948024
   PubMed Web of Science ®Google Scholar
• MaruthurNMTsengEHutflessSDiabetes medications as mono-therapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysisAnn Intern Med20161641174075127088241
   PubMed Web of Science ®Google Scholar
• GoringSHawkinsNWygantGRoudautMTownsendRWoodIBarnettAHDapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysisDiabetes Obes Metab201416543344224237939
   PubMed Web of Science ®Google Scholar
• TriccoACAntonyJKhanPASafety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysisBMJ Open20144e005752
   Web of Science ®Google Scholar
• PalmerSCMavridisDNicolucciAComparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysisJAMA2016316331332427434443
   PubMed Web of Science ®Google Scholar
• Patient-Centered Outcomes Research Institute (PCORI)Some PCORI-funded research projects focused on diabetes Available from: www.pcori.org/research-results/some-pcori-funded-research-projects-focused-diabetesAccessed July 7, 2016
   Google Scholar
• Hippisley-CoxJCouplandCDiabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary careBMJ2016352i1450 Available from: http://dx.doi.org/10.1136/bmj.i1450Accessed May 23, 201627029547
   PubMed Web of Science ®Google Scholar
• MorganCLMukherjeeJJenkins-JonesSHoldenSECurrieCJCombination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortalityDiabetes Obes Metab2014161097798324762119
   PubMed Web of Science ®Google Scholar
• OuSMShihCJChaoPWEffects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitusAnn Intern Med2015163966367226457538
   PubMed Web of Science ®Google Scholar
• EngelmannJManuwaldURubachCKuglerJBirkenfeldALHanefeldMRotheUDeterminants of mortality in patients with type 2 diabetes: a reviewRev Endocr Metab Disord201617112913727068710
   PubMed Web of Science ®Google Scholar
• CADTHCADTH Rapid Response ReportGlyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: A Review of the Clinical Effectiveness and Safety – An Update2015 Available from: https://www.cadth.ca/sites/default/files/pdf/htis/aug-2015/RC0693%20Glyburide%20Update%20Final.pdfAccessed July 20, 2016
   Google Scholar
• SimpsonSHLeeJChoiSVandermeerBAbdelmoneimASFeatherstoneTRMortality risk among sulfonylureas: a systematic review and network meta-analysisLancet Diabetes Endocrinol201531435125466239
   PubMed Web of Science ®Google Scholar
• TohAHamppCReichmanMERisk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs – a retrospective cohort studyAnn Intern Med20161641170571427110660
   PubMed Web of Science ®Google Scholar
• LiLLiSDengKDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesBMJ2016352i610 Available from: http://dx.doi.org/10.1136/bmj.i610Accessed May 23, 201626888822
   PubMed Web of Science ®Google Scholar
• SalvoFMooreNArnaudMAddition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysisBMJ2016353i2231 Available from: http://dx.doi.org/10.1136/bmj.i2231Accessed May 23, 201627142267
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• IngelfingerJRRosenCJCardiac and renovascular complications in type 2 diabetes – is there hope?N Engl J Med2016375438038227331286
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development LLCCANVAS – CANagliflozin cardioVascular Assessment Study (CANVAS) – a randomized, multi-center, double-blind, parallel, placebo-controlled study of the effects of JNJ-28431754 on cardiovascular outcomes in adult subjects with type 2 diabetes mellitus Available from: https://clinicaltrials.gov/ct2/show/NCT01032629. NLM identifier: NCT01032629Accessed July 7, 2016
   Google Scholar
• AstraZenecaMulticenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) – dapagliflozin effect on cardiovascular events a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of dapagliflozin 10 mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes Available from: https://clinicaltrials.gov/ct2/show/NCT01730534. NLM identifier: NCT01730534Accessed July 7, 2016
   Google Scholar
• IngelfingerJRosenCJCardiovascular risk and sodium–glucose cotransporter 2 inhibition in type 2 diabetesN Engl J Med2015373222178217926605932
   PubMed Web of Science ®Google Scholar
• MarsoSPDanielsGHBrown-FrandsenKLEADER Steering Committee on behalf of the LEADER Trial InvestigatorsLiraglutide and cardiovascular outcomes in type 2 diabetesN Eng J Med20163754311322
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)NICE guideline – type 2 diabetes in adults: management2015 Available from: https://www.nice.org.uk/guidance/ng28Accessed April 17, 2016
   Google Scholar
• NICENICE Algorithm for blood glucose lowering therapy in adults with type 2 diabetes2015 Available from: https://www.nice.org.uk/guidance/ng28/resources/algorithm-for-blood-glucose-lowering-therapy-in-adults-with-type-2-diabetes-2185604173Accessed April 17, 2016
   Google Scholar
• American Diabetes AssociationApproaches to glycemic treatmentDiabetes Care201639Suppl 1S52S5926696682
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association (CDA)Clinical practice guidelines: 2016 interim update to the guidelines – update to the pharmacologic management of type 2 diabetes2016 Available from: http://guidelines.diabetes.ca/2016updateAccessed July 19, 2016
   Google Scholar
• ThoumiAUdayakumarKDrobnickETaylorAMcClellanMInnovations in diabetes care around the world: case studies of care transformation through accountable care reformsHealth Aff201534914891497
   Web of Science ®Google Scholar